Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)

Next Previous
X
Search
Trial Profile

A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SNSP 113 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Anagram Therapeutics

    • Most Recent Events

    • 04 Apr 2023 According to an Anagram Therapeutics media release, Synspira changed its name to Anagram Therapeutics.
    • 23 May 2018 Status changed from recruiting to discontinued due to successful completion of Part A. Company decision to end early.
    • 03 Jan 2018 According to a Synspira media release, the phase Ia portion of this trial in healthy volunteers has been completed, and it will advance into stable CF patients in 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top